Biosimilar Antibodies

Bapineuzumab is a monoclonal antibody targeting the β-amyloid protein (APP), specifically designed for Alzheimer’s disease research. This antibody binds to the β-amyloid plaques, which are a hallmark of Alzheimer’s pathology, making it an essential tool for studies focused on disease mechanisms and potential therapeutic interventions.

Fasinumab is a human IgG4 monoclonal antibody specifically targeting nerve growth factor (NGF). This antibody is utilized in research focused on acute sciatica and knee osteoarthritis, providing a valuable tool for studies investigating the role of NGF in pain and inflammation associated with these conditions.

Sasanlimab (PF-06801591) is a humanized IgG4-κ monoclonal antibody designed to selectively target the Programmed Death-1 (PD-1) receptor. This antibody is produced in Chinese Hamster Ovary (CHO) cells, ensuring high fidelity and consistent performance in immunotherapy research. Sasanlimab is primarily utilized in studies focused on the modulation of immune checkpoints, which are critical for advancing cancer immunotherapy.

Elranatamab (PF-06863135) is a human IgG2κ monoclonal antibody targeting CD3E and TNFRSF17. For optimal experimental control, it is recommended to use Human IgG2 kappa as an isotype control.

Pelgifatamab (BAY-2315497) is a monoclonal antibody targeting the prostate-specific membrane antigen (PSMA). This antibody can be covalently attached to a 225Ac binding moiety, making it a valuable tool for research into metastatic castration-resistant prostate cancer (mCRPC). Pelgifatamab's specificity for PSMA and its potential for radioisotope conjugation facilitate its use in advanced prostate cancer studies, particularly in therapeutic research and radiolabeled imaging applications.

Minretumomab (CC-49) is a murine monoclonal antibody that targets TAG-72 (tumor-associated glycoprotein 72), a protein frequently overexpressed in various carcinomas. This antibody is extensively utilized in the study of cancer biology and immune response mechanisms, providing valuable insights into tumor markers and the development of therapeutic strategies.

Tuvirumab (OST 577; SDZ-OST 577) is a monoclonal antibody of the human IgG1 subclass, specifically targeting the hepatitis B virus surface antigen (HBsAg). It binds with high specificity and affinity, exhibiting a dissociation constant (Kd) of 3.6 nM for HBsAg. This antibody is primarily utilized in the study of chronic hepatitis B, offering significant potential for research applications in this area.

Izuralimab is a bispecific IgG1 monoclonal antibody designed for simultaneous targeting of the inducible T-cell costimulator (ICOS/CD278) and the programmed death-1 receptor (PD-1). This dual specificity facilitates a coordinated modulation of T-cell responses, enhancing immune activation against tumors while potentially mitigating autoimmune responses. Izuralimab is utilized predominantly in oncological research to investigate therapeutic strategies for enhancing antitumor immunity.

Netakimab is a monoclonal antibody targeting interleukin-17 (IL-17). This biologic is specifically designed for research applications related to ankylosing spondylitis, psoriatic arthritis, and moderate-to-severe plaque psoriasis. Netakimab's mechanism of action involves the inhibition of IL-17, a key cytokine involved in the inflammation and pathogenesis of various autoimmune disorders. This makes it a valuable tool for studies aiming to understand and potentially modulate immune responses in these conditions.

ABP 215 (Bevacizumab-awwb), a biosimilar to Bevacizumab, is a humanized IgG1 monoclonal antibody that specifically targets vascular endothelial growth factor A (VEGFA), thereby inhibiting its interaction with VEGF receptors. This antibody demonstrates anticancer properties by impeding angiogenesis, a critical process in tumor growth and metastasis. ABP 215 is utilized in research focused on metastatic colorectal cancer (mCRC), providing a valuable tool for investigating disease mechanisms and potential therapeutic interventions.

Emibetuzumab (LY2875358) is a humanized bivalent MET antibody of the IgG4 subtype, designed to exhibit potent neutralizing and internalizing capabilities. This antibody effectively inhibits both hepatocyte growth factor (HGF)-dependent and HGF-independent MET pathway activations, thereby impeding tumor growth. Emibetuzumab is primarily utilized in cancer research studies, focusing on its therapeutic potential and mechanism of action in oncogenic signaling and tumor progression.

Lixudebart is a humanized IgG1-kappa monoclonal antibody that specifically targets Claudin-1 (CLDN1). This antibody is designed for the study of CLDN1's role in tight junction integrity and its implications in various pathological conditions. Lixudebart's high specificity and affinity make it an ideal tool for detailed biochemical and cellular research applications.

Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody designed to simultaneously target PD-1 and CTLA-4. By inhibiting these checkpoint pathways, Cadonilimab effectively alleviates immunosuppression and reverses T cell exhaustion specific to tumor environments. This antibody notably reduces Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). Cadonilimab is applicable in research focused on metastatic cervical cancer and other malignancies, including gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, and non-small cell lung cancer (NSCLC), providing a valuable tool for investigations into immune checkpoint blockade and cancer immunotherapy.

Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.

Izalontamab (SI-B001) is a bispecific monoclonal antibody designed to selectively target the EGFR/HER3 heterodimer, demonstrating high specificity in its binding affinity. This antibody is primarily utilized in cancer research, facilitating the study of molecular pathways and potential therapeutic interventions related to EGFR and HER3 interactions.

LY3022855 is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CSF1R (Colony Stimulating Factor 1 Receptor), also known as M-CSFR or CD115. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Elarekibep (PRS-060/AZD1402) is a potent, long-acting full antagonist of the IL-4 receptor alpha (IL-4Ra), characterized by high affinity and slow dissociation rates. This agent is specifically designed for the study of Type 2 endotype asthma, providing a valuable tool for research into the pathophysiology and potential therapeutic interventions for this condition.

Moxetumomab is a human IgG1 κ monoclonal antibody targeting CD22. For optimal experimental control, it is recommended to use Human IgG1 kappa as an isotype control.

Aprutumab (BAY 1179470) is a fully human monoclonal antibody targeting the fibroblast growth factor receptor 2 (FGFR2). It exhibits specific binding affinity to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. This antibody is primarily explored for its applicability in the study of solid tumors, offering significant potential for research into cancer biology and therapeutic development.

Briquilimab (JSP-191) is a humanized monoclonal antibody engineered to target CD117 (c-Kit), facilitating the depletion of hematopoietic stem cells (HSCs). This antibody is characterized by its non-toxic profile, making it an ideal agent for clearing host marrow niche spaces. The primary application of Briquilimab is to enhance donor HSC engraftment and promote immune reconstitution, particularly in the treatment of severe combined immunodeficiency (SCID). This mechanism not only supports effective hematopoietic transplantation but also ensures safety and efficacy in clinical settings.

Bulumtatug is a human IgG1κ monoclonal antibody targeting Nectin-4. The recommended isotype control for experimental use is Human IgG1 kappa Isotype Control.

Urtoxazumab (TMA-15) is a humanized monoclonal antibody specifically targeting Shiga toxin 2 (Stx2). This antibody is designed to neutralize Stx2, a potent toxin produced by certain pathogenic strains of bacteria, thereby mitigating its effects in various biological and pathological processes. Urtoxazumab is utilized primarily in research focused on bacterial infections, particularly those involving Shiga toxin-producing organisms, and is instrumental in studying the mechanisms of toxin-induced cellular damage and the evaluation of therapeutic interventions.

Felmetatug is a human monoclonal antibody of the IgG1κ subtype that specifically targets VTCN1. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

The Anti-MHC Class I Antibody (W6/32) is a chimeric mouse monoclonal antibody of the IgG2a, κ isotype, specifically designed to target human MHC Class I molecules. For accurate isotype control in experimental procedures, it is recommended to use the Mouse IgG2a kappa, Isotype Control with this antibody. This product is essential for research focusing on the immune response, antigen presentation, and cellular immunity.

The Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a humanized monoclonal antibody, produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target VEGFR2/KDR/CD309. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and exhibits a molecular weight of approximately 145 kDa. For experimental control purposes, the Human IgG4 kappa Isotype Control is recommended. This product is essential for research focused on the biological pathways mediated by VEGFR2/KDR/CD309, including angiogenesis and vascular development, making it highly relevant in studies of cancer, cardiovascular diseases, and other angiogenesis-related disorders.

Envafolimab (ASC 22; KN 035) is a recombinant fusion protein comprising a humanized single-domain anti-PD-L1 antibody linked to the Fc fragment of a human IgG1 antibody. This biologic is designed to inhibit the interaction between PD-L1 and PD-1, exhibiting an IC50 value of 5.25 nM, indicative of its potent inhibitory activity. Envafolimab is primarily utilized in research focused on solid tumors, providing a valuable tool for investigating the therapeutic potential of PD-L1 blockade in oncology.

Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody designed to target a specific variant of the MUC5AC glycoprotein. This antibody exhibits high specificity for tumor-associated MUC5AC variants frequently expressed in colorectal and pancreatic cancers. Ensituximab's targeted mechanism of action makes it a valuable tool for research focused on these types of malignancies, providing potential insights into disease pathways and therapeutic approaches.

Zeripatamig is a human IgG1 κ monoclonal antibody targeting both CD19 and CD47 antigens. For accurate experimental controls, it is recommended to use Human IgG1 kappa Isotype Control.

Atenastobart is a human monoclonal antibody of the IgG1λ2 subtype that specifically targets TNFRSF9. For experimental control purposes, it is recommended to use Human IgG1 lambda2 as an isotype control.

LY2525623 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting interleukin-23 (IL-23). This antibody is comprised of a human IgG1 type heavy chain and a human kappa (huκ) type light chain, with an approximate molecular weight of 145 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Ragistomig is a monoclonal antibody of the IgG1 isotype, specifically targeting TNFRSF9/CD274. It is composed of two identical IgG1 heavy chains and a κ light chain paired with a variable region that includes a λ light chain. The antibody is structured as a dimer, ensuring stable binding and specificity to its antigen. This configuration makes Ragistomig suitable for research applications focused on the modulation and study of immune checkpoint pathways.

Anti-IL-13 (H2L6) is a humanized monoclonal antibody specifically targeting interleukin-13 (IL-13). This antibody is designed for the precise detection and neutralization of IL-13, a key cytokine involved in inflammatory responses and allergic reactions. It is applicable for use in various immunological assays, including ELISA, Western blotting, and immunohistochemistry, making it a valuable tool for research in immunology and inflammation.

The Anti-IL-15 Antibody (DISC0280) is a recombinant human monoclonal antibody expressed in Chinese Hamster Ovary (CHO) cells, specifically designed to target interleukin-15 (IL-15). This antibody is composed of a human IgG1 heavy chain and a human lambda light chain, and has a predicted molecular weight of 145 kDa. For isotype control purposes, the Human IgG1 kappa, Isotype Control is recommended. This product is ideal for research applications focusing on the biological activities and pathological roles of IL-15.

Denikitug is a chimeric antibody of the IgG1κ subtype that specifically targets CCR8. For experimental control purposes, Human IgG1 kappa Isotype Control is recommended.

Sugemalimab is a fully human, full-length monoclonal antibody of the immunoglobulin G4 (IgG4) subclass that targets programmed death ligand 1 (PD-L1). This antibody exhibits anticancer properties, making it particularly valuable for research into non-small cell lung cancer (NSCLC). Sugemalimab's specificity for PD-L1 enables it to modulate immune responses, which is critical for understanding tumor immune evasion mechanisms in NSCLC.

Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3, designed to inhibit the binding of LAG-3 to MHC class II molecules. This interaction blockade enhances T-cell function and may potentiate an anti-tumor immune response. Favezelimab is primarily investigated for its therapeutic potential in colorectal cancer research, particularly in combination with the PD-L1 inhibitor Pembrolizumab, to synergistically enhance immune-mediated tumor suppression.

Rosopatamab (HuJ591) is a humanized IgG1 monoclonal antibody targeting the Prostate-Specific Membrane Antigen (PSMA). This antibody is specifically designed for use in cancer research, with a particular focus on prostate cancer. Rosopatamab can be conjugated to lutetium-177 (177Lu), a low-energy beta-emitting radioisotope, via the bifunctional chelator DOTA-NHS ester. This conjugation facilitates the creation of a radioimmunoconjugate that selectively targets and efficiently eradicates malignant prostate cells. This specificity and efficiency make Rosopatamab an invaluable tool in the development of targeted radiotherapeutic strategies in oncology research.

The Anti-TM4SF1 Antibody (AGX-A07) is a humanized IgG1 monoclonal antibody specifically designed to target TM4SF1, a transmembrane protein implicated in cell signaling and tumor cell proliferation. For optimal use in experimental controls, it is recommended to utilize Human IgG1 kappa as an isotype control. This antibody serves as a valuable tool in research focused on cancer biology and therapeutic development.

Anti-CLDN6 Antibody (AB3-7) is a humanized monoclonal antibody specifically targeting CLDN6, expressed in Chinese Hamster Ovary (CHO) cells. This antibody is composed of an IgG1 heavy chain and a human kappa (huκ) light chain, with a predicted molecular weight of 78.02 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control, which matches the antibody's subclass and light chain type. This product is essential for research focusing on the role of CLDN6 in cellular and molecular biology studies.

Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody that targets the protective antigen (PA) of Bacillus anthracis. By binding to PA, Raxibacumab effectively inhibits the interaction of the antigen with its cellular receptors, preventing the entry and subsequent toxic effects of the anthrax toxin within host cells. This antibody is utilized primarily in research focused on anthrax prevention and therapy, offering a critical tool for studying the mechanisms of anthrax toxicity and the development of countermeasures.

Setoxaximab is a chimeric humanized antibody of the IgG1-κ isotype, specifically designed to target Shiga toxin type 1. This monoclonal antibody binds with high specificity and affinity to the toxin, potentially neutralizing its effects, which is crucial in studying bacterial pathogenesis and developing therapeutic strategies against Shiga toxin-producing bacterial infections.

Petosemtamab is a dual-target monoclonal antibody that selectively binds to both epidermal growth factor receptor (EGFR) and leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5). Expressed in Chinese hamster ovary (CHO) cells genetically engineered to lack the fucosyltransferase 8 gene (FUT8), this modification results in a fucose-deficient antibody that exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC). With dissociation constants (Kd) of 0.22 nM for EGFR and 0.86 nM for LGR5, Petosemtamab effectively inhibits EGFR signaling and induces receptor degradation in LGR5-positive cancer cells. This antibody is particularly relevant for research into solid tumors, including head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC), providing a valuable tool for studies aimed at understanding and potentially intervening in the pathways involved in these malignancies.

Mirzotamab is an IgG1κ monoclonal antibody specifically designed to target CD276 (also known as B7-H3), a protein frequently overexpressed in various tumor cells. This antibody exhibits potent anti-tumor properties. In its conjugated form, mirzotamab is linked to Clezutoclax, a BCL-2 family inhibitor, creating the antibody-drug conjugate (ADC) known as Mirzotamab Clezutoclax (ABBV-155). This ADC is currently under investigation for its efficacy in combination with taxane therapy in the treatment of relapsed or refractory solid tumors, highlighting its potential as a therapeutic in oncological research.

Lulizumab is a humanized recombinant antibody that acts as an antagonist to the CD28 domain. This antibody selectively targets the CD28 signal, effectively inhibiting T-cell activation. In research studies, specifically using a sensitized non-human primate kidney transplantation model, Lulizumab has demonstrated the ability to modulate immune cell responses. When used in combination with Carfilzomib, it has shown potential in prolonging graft survival times, indicating its utility in transplant immunology and immune regulation studies.

The Anti-LAP Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the latency-associated peptide (LAP). This antibody is composed of a human IgG2 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of approximately 150 kDa. Researchers seeking an isotype control for this antibody may utilize the Human IgG2 kappa, Isotype Control to ensure specificity and accuracy in their experimental applications. This product is ideal for use in various immunological assays to study the role and regulation of LAP in biological systems.

Anti-GPC3 Antibody (YP7) is a chimeric mouse monoclonal antibody of the IgG1 kappa subclass, specifically designed to target human Glypican 3 (GPC3). For optimal experimental control, the recommended isotype control is Mouse IgG1 kappa, Isotype Control. This antibody is ideal for research applications requiring precise GPC3 targeting.

Zelminemab (AMG-301) is a humanized monoclonal antibody designed to selectively inhibit the PACAP type I (PAC1) receptor. This targeted approach offers potential therapeutic applications in the modulation of pathways involved in various neurological disorders.

Feladilimab (GSK3359609) is a humanized IgG4 monoclonal antibody that functions as an agonist targeting ICOS (CD278). This antibody selectively binds to ICOS-expressing T cells, a critical interaction in the modulation of immune responses. Due to its mechanism of action, Feladilimab is primarily investigated for its potential applications in cancer research, where it may influence T cell activity and tumor immune evasion.

Omoprubart is a humanized monoclonal antibody of the IgG2-G4 κ subtype, specifically targeting the complement component 5 (C5). This antibody is designed for therapeutic interventions in diseases mediated by the complement system.

Placulumab (ART621) is a monoclonal antibody targeting tumor necrosis factor alpha (TNF α), exhibiting potent anti-inflammatory properties. This biologic is designed for the investigation and potential treatment of various inflammatory disorders, including arthritis, where TNF α plays a critical role in disease pathogenesis. Placulumab's specificity for TNF α makes it a valuable tool in research focused on elucidating the mechanisms of inflammation and in clinical settings addressing TNF α-mediated conditions.